Paolo Gandellini

List of Publications by Year
in descending order

55 papers	2,854 citations	172457 29 h-index	189892 50 g-index
55 all docs	55 docs citations	55 times ranked	7052 citing authors

#	Article	IF	Citations
1	Reciprocal Metabolic Reprogramming through Lactate Shuttle Coordinately Influences Tumor-Stroma Interplay. Cancer Research, 2012, 72, 5130-5140.	0.9	438
2	miR-205 Exerts Tumor-Suppressive Functions in Human Prostate through Down-regulation of Protein Kinase CÎµ. Cancer Research, 2009, 69, 2287-2295.	0.9	334
3	miR-21: an oncomir on strike in prostate cancer. Molecular Cancer, 2010, 9, 12.	19.2	189
4	Large oncosomes mediate intercellular transfer of functional microRNA. Cell Cycle, 2013, 12, 3526-3536.	2.6	189
5	Senescent stroma promotes prostate cancer progression: The role of miRâ€210. Molecular Oncology, 2014, 8, 1729-1746.	4.6	102
6	Complexity in the tumour microenvironment: Cancer associated fibroblast gene expression patterns identify both common and unique features of tumour-stroma crosstalk across cancer types. Seminars in Cancer Biology, 2015, 35, 96-106.	9.6	85
7	miR-205 impairs the autophagic flux and enhances cisplatin cytotoxicity in castration-resistant prostate cancer cells. Biochemical Pharmacology, 2014, 87, 579-597.	4.4	83
8	MicroRNAs as new therapeutic targets and tools in cancer. Expert Opinion on Therapeutic Targets, 2011, 15, 265-279.	3.4	81
9	Antisense oligonucleotide-mediated inhibition of hTERT, but not hTERC, induces rapid cell growth decline and apoptosis in the absence of telomere shortening in human prostate cancer cells. European Journal of Cancer, 2005, 41, 624-634.	2.8	80
10	miR-875-5p counteracts epithelial-to-mesenchymal transition and enhances radiation response in prostate cancer through repression of the EGFR-ZEB1 axis. Cancer Letters, 2017, 395, 53-62.	7.2	80
11	miR-205 regulates basement membrane deposition in human prostate: implications for cancer development. Cell Death and Differentiation, 2012, 19, 1750-1760.	11.2	77
12	Mesenchymal to amoeboid transition is associated with stem-like features of melanoma cells. Cell Communication and Signaling, 2014, 12, 24.	6.5	77
13	miR-205 enhances radiation sensitivity of prostate cancer cells by impairing DNA damage repair through PKCÎµ and ZEB1 inhibition. Journal of Experimental and Clinical Cancer Research, 2019, 38, 51.	8.6	64
14	miR-205 Hinders the Malignant Interplay Between Prostate Cancer Cells and Associated Fibroblasts. Antioxidants and Redox Signaling, 2014, 20, 1045-1059.	5.4	63
15	Integrated gene and miRNA expression analysis of prostate cancer associated fibroblasts supports a prominent role for interleukin-6 in fibroblast activation. Oncotarget, 2015, 6, 31441-31460.	1.8	55
16	Towards the definition of prostate cancer-related microRNAs: where are we now?. Trends in Molecular Medicine, 2009, 15, 381-390.	6.7	54
17	Biological relevance and therapeutic potential of G-quadruplex structures in the human noncoding transcriptome. Nucleic Acids Research, 2021, 49, 3617-3633.	14.5	50
18	Apollon gene silencing induces apoptosis in breast cancer cells through p53 stabilisation and caspase-3 activation. British Journal of Cancer, 2009, 100, 739-746.	6.4	47

#	Article	IF	Citations
19	Down-regulation of human telomerase reverse transcriptase through specific activation of RNAi pathway quickly results in cancer cell growth impairment. Biochemical Pharmacology, 2007, 73, 1703-1714.	4.4	45
20	LEADeR role of miR-205 host gene as long noncoding RNA in prostate basal cell differentiation. Nature Communications, 2019, 10, 307.	12.8	44
21	microRNAs as players and signals in the metastatic cascade: Implications for the development of novel anti-metastatic therapies. Seminars in Cancer Biology, 2017, 44, 132-140.	9.6	42
22	Coated cationic lipid-nanoparticles entrapping miR-660 inhibit tumor growth in patient-derived xenografts lung cancer models. Journal of Controlled Release, 2019, 308, 44-56.	9.9	41
23	Splicing modulation as novel therapeutic strategy against diffuse malignant peritoneal mesothelioma. EBioMedicine, 2019, 39, 215-225.	6.1	41
24	miRNAs in tumor radiation response: bystanders or participants?. Trends in Molecular Medicine, 2014, 20, 529-539.	6.7	40
25	Antitumor activity of miR-34a in peritoneal mesothelioma relies on c-MET and AXL inhibition: persistent activation of ERK and AKT signaling as a possible cytoprotective mechanism. Journal of Hematology and Oncology, 2017, 10, 19.	17.0	40
26	Anti-tumor activity of selective inhibitors of XPO1/CRM1-mediated nuclear export in diffuse malignant peritoneal mesothelioma: the role of survivin. Oncotarget, 2015, 6, 13119-13132.	1.8	39
27	Targeting the telosome: Therapeutic implications. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2009, 1792, 309-316.	3.8	37
28	Unveiling the ups and downs of miR-205 in physiology and cancer: transcriptional and post-transcriptional mechanisms. Cell Death and Disease, 2020, 11, 980.	6.3	36
29	MicroRNAs: Cobblestones on the Road to Cancer Metastasis. Critical Reviews in Oncogenesis, 2013, 18, 341-355.	0.4	36
30	PKC-alpha modulation by miR-483-3p in platinum-resistant ovarian carcinoma cells. Toxicology and Applied Pharmacology, 2016, 310, 9-19.	2.8	33
31	Emerging role of microRNAs in prostate cancer: implications for personalized medicine. Discovery Medicine, 2010, 9, 212-8.	0.5	25
32	Photochemically enhanced delivery of a cell-penetrating peptide nucleic acid conjugate targeting human telomerase reverse transcriptase: effects on telomere status and proliferative potential of human prostate cancer cells. Cell Proliferation, 2007, 40, 905-920.	5.3	24
33	miR-380-5p-mediated repression of TEP1 and TSPYL5 interferes with telomerase activity and favours the emergence of an â€œALT-likeâ€•phenotype in diffuse malignant peritoneal mesothelioma cells. Journal of Hematology and Oncology, 2017, 10, 140.	17.0	23
34	Dissecting the role of microRNAs in prostate cancer metastasis: implications for the design of novel therapeutic approaches. Cellular and Molecular Life Sciences, 2016, 73, 2531-2542.	5.4	22
35	MicroRNAs in Cancer Management: Big Challenges for Small Molecules. BioMed Research International, 2015, 2015, 1-2.	1.9	17
36	MicroRNA-Mediated Control of Prostate Cancer Metastasis: Implications for the Identification of Novel Biomarkers and Therapeutic Targets. Current Medicinal Chemistry, 2013, 20, 1566-1584.	2.4	15

#	Article	IF	Citations
37	MicroRNA-dependent Regulation of Telomere Maintenance Mechanisms: A Field as Much Unexplored as Potentially Promising. Current Pharmaceutical Design, 2014, 20, 6404-6421.	1.9	14
38	RNA Interference-Mediated Validation of Survivin and Apollon/BRUCE as New Therapeutic Targets for Cancer Therapy. Current Topics in Medicinal Chemistry, 2012, 12, 69-78.	2.1	12
39	Targeting MicroRNAs to Withstand Cancer Metastasis. Methods in Molecular Biology, 2015, 1218, 415-437.	0.9	11
40	miR-1272 Exerts Tumor-Suppressive Functions in Prostate Cancer via HIP1 Suppression. Cells, 2020, 9, 435.	4.1	11
41	SPOP Deregulation Improves the Radiation Response of Prostate Cancer Models by Impairing DNA Damage Repair. Cancers, 2020, 12, 1462.	3.7	8
42	Prediction of Grade Reclassification of Prostate Cancer Patients on Active Surveillance through the Combination of a Three-miRNA Signature and Selected Clinical Variables. Cancers, 2021, 13, 2433.	3.7	8
43	Core Biopsies from Prostate Cancer Patients in Active Surveillance Protocols Harbor PTEN and MYC Alterations. European Urology Oncology, 2019, 2, 277-285.	5.4	7
44	Noncoding RNAs in the Interplay between Tumor Cells and Cancer-Associated Fibroblasts: Signals to Catch and Targets to Hit. Cancers, 2021, 13, 709.	3.7	7
45	MIR205HG/LEADR Long Noncoding RNA Binds to Primed Proximal Regulatory Regions in Prostate Basal Cells Through a Triplex- and Alu-Mediated Mechanism. Frontiers in Cell and Developmental Biology, 0, 10, .	3.7	6
46	MicroRNAs and the Response of Prostate Cancer to Anti-Cancer Drugs. Current Drug Targets, 2016, 17, 257-265.	2.1	5
47	Clusterin: A potential target for improving response to antiestrogens. International Journal of Oncology, 1992, 33, 791.	3.3	4
48	Gene expression dataset of prostate cells upon MIR205HG/LEADR modulation. Data in Brief, 2020, 29, 105139.	1.0	4
49	miR-550a-3p is a prognostic biomarker and exerts tumor-suppressive functions by targeting HSP90AA1 in diffuse malignant peritoneal mesothelioma. Cancer Gene Therapy, 2022, 29, 1394-1404.	4.6	3
50	Predicting and Understanding Cancer Response to Treatment. Disease Markers, 2018, 2018, 1-2.	1.3	2
51	miR-1227 Targets SEC23A to Regulate the Shedding of Large Extracellular Vesicles. Cancers, 2021, 13, 5850.	3.7	2
52	Coding the noncoding: 2 years of advances in the field of microRNAs and long noncoding RNAs. Cancer Gene Therapy, 2021, 28, 355-358.	4.6	1
53	Abstract B18: MiR-205 puts the brakes on the malignant interplay between prostate cancer cells and associated fibroblasts. , 2013, , .		1
54	MicroRNAs in Prostate Cancer: A Possible Role as Novel Biomarkers and Therapeutic Targets?. , 2011, , 145-162.		0

#	Article	IF	Citations
55	Abstract 19: Antitumor activity of selective inhibitors of XPO1/CRM1-mediated nuclear export in diffuse malignant peritoneal mesothelioma: the role of survivin. , 2015, , .		0